CMC-544 and Allogeneic Transplantation for CD22 Positive-Lymphoid Malignancies
Phase 1/2 Completed
27 enrolled 12 charts
Dose Adjusted EPOCH Regimen in Combination With Ofatumumab or Rituximab in Treating Patients With Newly Diagnosed or Relapsed or Refractory Burkitt Lymphoma or Relapsed or Refractory Acute Lymphoblastic Leukemia
Phase 2 Completed
14 enrolled 10 charts
Clofarabine, Idarubicin, Cytarabine, Vincristine Sulfate, and Dexamethasone in Treating Patients With Newly Diagnosed or Relapsed Mixed Phenotype Acute Leukemia
Phase 2 Completed
16 enrolled 9 charts
Umbilical Cord Blood Transplant With Added Sugar and Chemotherapy and Radiation Therapy in Treating Patients With Leukemia or Lymphoma
Phase 2 Completed
6 enrolled 10 charts
Engineered Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies
Phase 1 Completed
11 enrolled
Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
Phase 2 Completed
54 enrolled 13 charts
Bortezomib, Rituximab, and Dexamethasone With or Without Temsirolimus in Treating Patients With Untreated or Relapsed Waldenstrom Macroglobulinemia or Relapsed or Refractory Mantle Cell or Follicular Lymphoma
Phase 1/2 Completed
9 enrolled 8 charts
Personalized Kinase Inhibitor Therapy Combined With Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia
Phase 1 Completed
7 enrolled
Bortezomib and Chemotherapy in Treating Participants With Lymphoid Malignancies Undergoing Stem Cell Transplant
Phase 2 Completed
40 enrolled 11 charts